Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Bellanger

Showing results (21-30 of 22) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 22 results.
European Cytokine Network|March 8, 2000
Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia in first complete remissionD Blaise, M Attal, J Reiffers, et al.
Leukemia & Lymphoma|May 1, 1997
The use of a sequential high dose recombinant interleukin 2 regimen after autologous bone marrow transplantation does not improve the disease free survival of patients with acute leukemia transplanted in first complete remissionD Blaise, M Attal, J L Pico, et al.
Pageof 3

Showing results (21-30 of 22) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 22 results.
European Cytokine Network|March 8, 2000
Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia in first complete remissionD Blaise, M Attal, J Reiffers, et al.
Leukemia & Lymphoma|May 1, 1997
The use of a sequential high dose recombinant interleukin 2 regimen after autologous bone marrow transplantation does not improve the disease free survival of patients with acute leukemia transplanted in first complete remissionD Blaise, M Attal, J L Pico, et al.
Pageof 3